Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab-Reference-Cited by-同舟云学术

Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

Published:2021-12-01 Issue:12 Volume:78 Page:1510
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Brill Livnat¹,Rechtman Ariel¹,Zveik Omri¹,Haham Nitzan¹,Oiknine-Djian Esther²³,Wolf Dana G.²³,Levin Netta¹,Raposo Catarina⁴,Vaknin-Dembinsky Adi¹

Affiliation:

1. Faculty of Medicine, Hebrew University of Jerusalem, Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah Medical Center, Ein–Kerem, Jerusalem, Israel

2. Clinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel

3. Lautenberg Center for General and Tumor Immunology, The Hebrew University Faculty of Medicine, Jerusalem, Israel

4. F. Hoffmann-La Roche Ltd, Basel, Switzerland

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2784449/jamaneurology_brill_2021_br_210004_1638811692.855.pdf

Reference15 articles.

1. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis.;Salter;JAMA Neurol,2021

2. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.;Sahin;Nature,2020

3. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.;Baden;N Engl J Med,2021

4. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.;Khoury;Nat Med,2021

5. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.;Nelde;Nat Immunol,2021

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study;Frontiers in Immunology;2024-08-19

2. Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants;Science Bulletin;2024-08

3. De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate;Advances in Therapy;2024-06-11

4. Multiple sclerosis and COVID-19: a northern China survey;Neurological Sciences;2024-05-09

5. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination;Annals of Clinical and Translational Neurology;2024-05-07